Pfizer Introduction And Shareholder Analysis Research Proposal

PAGES
8
WORDS
2143
Cite

3% is in the middle. These figures indicate that Pfizer's returns are about average. Aside from an unusually good year in 2007 with respect to their returns, the company is rangebound in terms of its managerial efficiency. Recapturing the 2007 successes would be more encouraging but at present there is little to indicate a long-term trend of improved returns on either equity or assets.

Analysis

Pfizer's performance in the past five years has been uninspiring. The firm has been relatively stationery, especially with respect to revenues. Their business seems to be maturing as well, supported by the fact that the company has steadily increased its dividend. Indeed, without top line growth to attract investors, Pfizer has little choice but to increase the dividend in order to stem the sale of the firm's stock.

Pfizer stock has suffered more than would be expected given the firm's beta. There are two industry factors that make this especially alarming. The first is that pharmaceuticals are demand inelastic, both in terms of price and in terms of the economy. These drugs are a quality of life issue for many, so demand should not fall in light of a financial crisis. Indeed, Pfizer's revenues have remained constant through the crisis. Therefore, the damage to the firm' stock is not related to the market overall.

Rather, it is likely related to concern in the industry with respect to the impact of possible health care reform, and with respect to the skyrocketing cost of drug trials resulting from stricter FDA guidelines. Pfizer also carries some firm-specific issues that have damaged its stock. The company has not been able to increase its revenue over the past five years. Operating income has declined in that period, as has the firm's asset base and the book value of its equity. At best, Pfizer is holding steady; at worst it is shrinking.

This has taken all growth components out of the firm's stock. Management...

...

This increases the return to investors but has not done so enough to compensate for the removal of growth from Pfizer's economic model.
In the past year, Pfizer has seen some difficulties. Although the bottom line number is better, the company has been subject to a decline in many key metrics. Its current and quick ratios are down. Inventory levels are up and inventory turn is down. While receivables turn is down, it is not unusual for a firm facing difficult financial times to squeeze its customers for quicker payment, especially in light of the fact that collection for Pfizer was in the 2 1/2-month range in 2007.

Pfizer has also increased its debt level recently. After maintaining a stable capital structure for years, the company has finally taken on more debt in order to meet its cash flow needs. This will increase the firm's risk at a point when its business is maturing, which is not a cause of optimism. However, in light of the broader business cycle it is important to remember that rough times do happen and Pfizer's leverage is neither unusual nor dangerous.

Given what has been gleaned from this analysis, I would not purchase Pfizer stock. Nor would I have a few years ago. The stock's performance has been below expectations, and there are major structural reasons for that. The company has stagnated, and increases to dividend yields have not offset the lost growth potential.

There are fundamental issues holding back Pfizer as well. The company's industry is beset with uncertainty and a rising cost structure. The monopoly rents still make being in the pharmaceutical business worthwhile, and Pfizer's healthy margins reflect that. However, the company has certainly not excelled in the difficult circumstances. The returns on Pfizer in recent years have been dismal, and there is no evidence to…

Sources Used in Documents:

Works Cited:

Some financials from MSN Moneycentral. (2009). Retrieved November 20, 2009 from http://moneycentral.msn.com/investor/invsub/results/statemnt.aspx?Symbol=PFE&lstStatement=Income&stmtView=Ann


Cite this Document:

"Pfizer Introduction And Shareholder Analysis" (2009, November 19) Retrieved June 24, 2024, from
https://www.paperdue.com/essay/pfizer-introduction-and-shareholder-analysis-17293

"Pfizer Introduction And Shareholder Analysis" 19 November 2009. Web.24 June. 2024. <
https://www.paperdue.com/essay/pfizer-introduction-and-shareholder-analysis-17293>

"Pfizer Introduction And Shareholder Analysis", 19 November 2009, Accessed.24 June. 2024,
https://www.paperdue.com/essay/pfizer-introduction-and-shareholder-analysis-17293

Related Documents

business model canvas developed by Osterwalder and Pigneur in order to evaluate and diagnose Pfizer Inc. organizational model. This is done to provide recommendations for improvements as identified using the canvas model. Key areas of internal assessment include its products and services offerings, key resources, capabilities and competitive advantages. Key areas of external assessment include Porter's five forces, including but not limited to, key products, major competitors, new entry

JOHNSON & JOHNSON The Fundamental Analysis of Johnson & Johnson Inc. (J& J, 2005) Economic and Market Analysis Globalization Industry Analysis Company Analysis Brief History of the Company Analysis of Capital Asset Pricing Model Intrinsic Value Valuation Measures Trading Information Competitors Awards & Recognition Our modern business world consists of an extremely competitive global economy where manufactures search for opportunities to strategically reduce costs and increase market share and profitability. Historically, the most often chosen solution for holding down costs was to systematically reduce

Introduction to Johnson and Johnson For a company to be successful, it must continuously build and nurture long-term relationships with its strategic shareholders. Shareholders is anyone who has an interest in an organization ((Noe et al., 2016). They include employees, governments, competitors, suppliers, competitors and customers. One such company is Johnson and Johnson (J&J). It has emerged as one of the most successful company globally because of its values dubbed "Our

Market Driven Management
PAGES 75 WORDS 25695

Pharmaceutical industries have to operate in an environment that is highly competitive and subject to a wide variety of internal and external constraints. In recent times, there has been an increasing trend to reduce the cost of operation while competing with other companies that manufacture products that treat similar afflictions and ailments. The complexities in drug research and development and regulations have created an industry that is subject to intense

Corporate Social Responsibility in Indian Pharmaceutical Industry An Exploratory Study Outlook of CSR in India History of CSR in India Philanthropy in Indian Society Modern Form of CSR in Indian Society Profile of Indian Pharmaceutical Industry Rationale for Selection CSR Activities by Indian Pharmaceutical Companies Major Influences Over CSR Activities Scope of CSR Activities Comparison of Indian & Western Pharmaceutical Companies This research paper is concerned with the recent practices of Indian pharmaceutical companies in the field of corporate social responsibility. For

While Cadbury was initially vulnerable resulting in this take over, Kraft had to borrow heavily to afford the final price of 850p per share. In the coming months and years, Kraft will have to balance against recovering the money put into this acquisition (Wiggins, 2010). A risk, many British politicians and citizens alike fear will mean the end of their signature chocolate in an effort by Kraft to increase